CD25+ CD4+ regulatory T-cells in cancer

Immunol Res. 2005;32(1-3):155-68. doi: 10.1385/IR:32:1-3:155.

Abstract

Regulatory T-cells (Treg) protect the host from autoimmune disease by suppressing self-reactive immune cells. As such, Treg may also block antitumor immune responses. Recent observations by us and others showed that the prevalence of Treg is increased in cancer patients, particularly in the tumor environment. Our studies in a mouse pancreas cancer model suggest that the tumor actively promotes the accrual of Treg through several mechanisms involving activation of naturally occurring Treg as well as conversion of non-Treg into Treg. Our studies focus on further defining these mechanisms with the ultimate goal of designing strategies that block Treg-mediated suppression in cancer patients.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • Biomarkers, Tumor / immunology
  • Breast Neoplasms / immunology
  • CD4 Antigens / metabolism
  • Cancer Vaccines / therapeutic use
  • Carcinoma, Ductal, Breast / immunology
  • Dendritic Cells / immunology
  • Dendritic Cells / pathology
  • Female
  • Forkhead Transcription Factors / deficiency
  • Forkhead Transcription Factors / genetics
  • Forkhead Transcription Factors / immunology
  • Humans
  • Immune Tolerance
  • Lymphocyte Depletion
  • Mice
  • Mice, Knockout
  • Neoplasms / immunology*
  • Neoplasms / pathology
  • Neoplasms / therapy
  • Pancreatic Neoplasms / immunology
  • Pancreatic Neoplasms / therapy
  • Phenotype
  • Receptors, Interleukin-2 / metabolism
  • T-Lymphocytes, Regulatory / immunology*
  • Transforming Growth Factor beta / metabolism

Substances

  • Biomarkers, Tumor
  • CD4 Antigens
  • Cancer Vaccines
  • Forkhead Transcription Factors
  • Foxp3 protein, mouse
  • Receptors, Interleukin-2
  • Transforming Growth Factor beta